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Abstract
Background Preclinical data have suggested involvement of the
endocannabinoid (eCB) system inMDMA-inducedmemory im-
pairment. Clinical research has shown that blockade of the 5-HT2
receptor nulls memory impairment during MDMA intoxication.
Interestingly, studies have demonstrated that the eCB and the 5-
HT system interact. It was hypothesized that MDMA would
cause an increase in eCB concentrations together with a decrease
in memory performance, and that combining MDMAwith a 5-
HT2 receptor blocker ketanserin would lead to a counteraction of
the MDMA effects on eCB concentrations and memory.
Methods Twenty healthy recreational polydrug users entered a
double-blind placebo-controlled within-subject study.
Participants received a pre-treatment (ketanserin 40mg, placebo)
followed 30 min later by a treatment (MDMA 75 mg, placebo).
Verbal memory was tested by means of a 30-word learning test.
Endocannabinoid concentrations (anandamide (2-AG); N-
arachidonylethanolamine (AEA)) were assessed in blood at
baseline, before (90 min post-treatment) and after cognitive tests
(150 min post-treatment).
Results Findings showed that MDMA impaired memory
90 min post-treatment in the word learning task. This effect
was a replication of previous studies using the same dose of
MDMA (75 mg) and the same learning paradigm. Contrary to
our hypothesis, MDMA did not affect eCB concentrations,
nor did ketanserin block MDMA-induced memory impair-
ment. Ketanserin caused an increase in AEA concentrations,
180 min after administration.
Conclusion Current findings suggest that peripherally mea-
sured endocannabinoids are not associated with the verbal
memory deficit during MDMA intoxication. Trial registration
number: NTR3691.
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Introduction
Previous placebo-controlled experimental studies have con-
sistently shown that a single dose (75 mg) of (R,S)-3,4
methylenedioxymethamphetamine (MDMA) impairs memo-
ry for verbal information (e.g., de Sousa Fernandes Perna et al.
2014; Kuypers and Ramaekers 2005). The neurobiological
mechanism underlying this impairment has been studied and
it was suggested that the MDMA-induced elevation in plasma
cortisol concentrations was not related to the observed deficit
(Kuypers et al. 2013). van Wel and colleagues demonstrated
that blockade of the serotonin-2A (5-HT2A) receptor, by
means of a single dose of ketanserin, prevented the memory
impairment after a single dose of MDMA (van Wel et al.
2011). The detailed neurobiological mechanism behind the
MDMA-induced memory deficit has yet to be elucidated.
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There is evidence suggesting that the serotonergic neurotrans-
mission system is modulated by the endocannabinoid (eCB) sys-
tem. Specifically, the CB1 receptor modulates the excitability of
dorsal raphe serotonin neurons (Haj-Dahmane and Shen 2011),
and more relevant in the context of the findings by vanWel et al.
(2011), 5-HT2A receptor activation stimulates the formation and
release of 2-arachidonoylglycerol (2-AG), an endocannabinoid
(Parrish and Nichols 2006). The best characterized eCBs are 2-
AG and AEA (N-arachidonylethanolamine, anandamide), and
both of these lipids exert agonist activity at CB1 and CB2 recep-
tors. They are synthetized on an Bon-demand^ basis and crucial
in certain forms of neuronal plasticity (Curran et al. 2016). Since
MDMA acts on the 5-HT2A receptor (Erritzoe et al. 2011; van
Wel et al. 2011), it can be hypothesized that this also has impli-
cations for endocannabinoid concentrations.
Converging data suggest that MDMA and (exogenous and
endogenous) cannabinoids interact pharmacologically (Valverde
and Rodriguez-Arias 2013). Both MDMA-induced conditioned
place preference and self-administration in rats are under endog-
enous tonic control by the endocannabinoid system (Braida et al.
2005; Braida and Sala 2002). Low doses of THC have been
demonstrated to modulate MDMA-induced behavioral effects,
decreasing conditioned place preference (Robledo et al. 2007).
In line with this, combined THC-MDMA administration led to
synergistic effects on working memory in rats; MDMA in low-
to-high doses led to an exacerbation of the THC-induced mem-
ory impairment (Young et al. 2005). Interestingly, MDMA-
induced memory impairment in rats could be blocked with a
CB1 receptor antagonist (Nawata et al. 2010).
Together, these data suggest involvement of the
endocannabinoid system in MDMA-induced memory impair-
ment. The present study was therefore set up to study the
association between endocannabinoid concentrations and ver-
bal memory performance during MDMA intoxication. It was
hypothesized that MDMA would cause an increase in eCB
concentrations together with a decrease in verbal memory
performance. In addition, given the role of the 5-HT2A recep-
tor in memory, and its interaction with the eCB system, it was
hypothesized that pretreatment with ketanserin, a 5-HT2A re-
ceptor blocker, would counteract the effects of MDMA on
endocannabinoid release and memory.
Methods
Participants
Participants were 20 healthy polydrug MDMA users (mean
(SD) age = 21.2 (2.6); 8 females), who previously used
ecstasy/MDMA (16.8 (23.2) times) and other recreational
drugs (e.g., cocaine, amphetamine, and cannabis). The mean
(SD) verbal IQ was 103.9 (4.9) as determined by the National
Adult Reading Test on the training session, preceding the test
sessions (Bright et al. 2002).
Participantswere recruited through advertisements in univer-
sitybuildings, via awebsite (digi-prik.nl), andbywordofmouth.
Design and treatments
The study was conducted according to a two-by-two double-
blind, placebo-controlled within-subject design with pre-
treatment (ketanserin 40 mg or placebo) preceding the treat-
ment (MDMA 75 mg or placebo) by 30 min (Brogden and
Sorkin 1990; Sharpley et al. 1994). A double-dummy proce-
dure was used to control for differences in Tmax between both
drugs. Tmax of MDMA is 2 h (de la Torre et al. 2004) and Tmax
of ketanserin is between 0.5 and 4 h (Heykants et al. 1986;
Persson et al. 1991; Reimann et al. 1983). The timing of the
(pre-) treatment was based on similar research conducted by
the same group (van Wel et al. 2011; van Wel et al. 2012)
where it was shown that the MDMA-induced elevated mood
state was blocked by ketanserin (van Wel et al. 2012).
The 75-mg dose ofMDMAwas selected because it has con-
sistently been shown to impair memory performance and to
produce robust subjective mood changes in a number of previ-
ous studies from our lab (Kuypers and Ramaekers 2005, 2007;
Kuypers et al. 2016; Ramaekers et al. 2009). Ketanserin 40mg
represents a regular therapeutic dose that blocks 91% of 5-HT2
receptors (Brogden and Sorkin 1990; Sharpley et al. 1994).
A permit for obtaining, storing, and administering MDMA
was obtained from the Dutch drug enforcement administration.
Randomization of pre-treatment and treatment conditions was
generated bymeans of a Latin square, with each participant being
assigned to a treatment sequence.
Procedures
Prior to participation, all participants were medically assessed by
a physician, who examined general health, including an ECG,
and who took blood and urine samples for standard chemistry
and hematology. In addition, participants were familiarized with
the procedures, tests, and questionnaires on a training day, pre-
ceding actual test days. On the training day, participants were
shown the questionnaires so that they knew what they looked
like, and they had to run through all tests so that they understood
what was expected. The order of the questionnaires and tests was
kept the same as on an actual test day. No learning effects were
expected on the tests that were used though parallel versions of
the word learning test were used so that each test day participants
had to learn a new list and no interference was possible.
Participants were requested to abstain from any drug use
1 week before the medical examination until the last test day.
They were asked not to use any caffeinated or alcoholic bev-
erages 24 h before testing and to get a normal night sleep as
assessed with the Groninger Sleep Scale.
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A test day started at 9 am with a screen for drugs of abuse in
urine (THC/opiates/cocaine/amphetamines/methamphet-
amines), a breathalyzer ethanol test, and a pregnancy test for
women. When tests were negative, participants had breakfast
and a blood samplewas taken. At 9:30 am, participants received
the pre-treatment followed 30 min later by the treatment.
Participants were then seated in a waiting room. At 11:25 am, a
second blood sample was taken. Thereafter, the word learning
task was assessed followed by a 1-h test battery consisting of
social behavior tests (Approach Avoidance Test with emotional
and social situation stimuli, Processing of Sounds Task) and
questionnaires (Dissociative Experiences Scale, Clinician
Administered Dissociative States Scale, Profile of Mood
States); these data are reported elsewhere (Kuypers et al. 2017;
Puxtyetal.2017).Thetestdayendedwith thecollectionofa third
blood sample. The study consisted of four test days that were
minimally separated by a 7-daywash-out period.
The study was performed in accordance with the Helsinki
Declaration of 1975, and its subsequent amendments, and was
approved by the Medical Ethics Committee of the Academic
Hospital of Maastricht and the University of Maastricht. All par-
ticipants gave their written informed consent after description of
the study and they were paid upon completion of the testing pe-
riods for their participation.
Word learning task
The 30-word learning task consists of 30 Dutch mono-syllabic
meaningful nouns (N = 18) and adjectives (N = 12) which are
consecutively presented on a computer screen (Kuypers et al.
2013; Rey 1958). The words are either neutral (N = 6) or had a
valence(positive(N = 12)ornegative(N = 12)).Thewords in the
lists of the five parallel versions (4 + 1 for test days + training
session) had been matched for abstraction. Participants had to
recall verbally as many words as possible (immediate recall).
This procedurewas repeated three times; immediate scoreswere
summed to comprise the Btotal immediate recall^ score. After a
30-mindelay, participantswereasked to recall (Bdelayed recall^)
as many of the previously learnt words as possible. Hereafter,
participants were given a delayed recognition task containing
30 new words and all the words of the previously shown list.
Participants’ task was to indicate whether the presented word
was a new one or one from the original list. Dependent variables
were number of correct recalled words per trial, the immediate
recall (IR) total score, the delayed recall (DR) score, the delayed
recognition score (total number of correct items of the original
list; max score = 30), and corresponding RTs.
National Adult Reading Test
The Dutch version of the National Adult Reading Test was
used to estimate the premorbid verbal intelligence of partici-
pants (Bright et al. 2002; Schmand et al. 1991).
Groninger Sleep Scale
The Groninger Sleep Scale assesses sleep quality and quantity
(hours of sleep). It consists of 15 dichotomous questions about
sleep complaints and an open question concerning the dura-
tion of sleep. The number of hours sleep and the total score on
this questionnaire were compared over the four test days to
ascertain that participants had an equal amount of sleep quan-
tity and quality before each test day (Mulder-Hajonides van
der Meulen et al. 1980).
Pharmacokinetics and endocannabinoid concentrations
Blood samples preserved with EDTA were collected three
times on each test day, at baseline, 90 min after treatment,
and 150 min after treatment, in order to determine
endocannabinoid (AEA, 2-AG) concentrations and pharma-
cokinetics of MDMA and ketanserin. Samples were centri-
fuged immediately and resulting plasma was stored at −
20 °C until analysis.
MDMA and ketanserin blood concentrations
MDMAwasdeterminedbygaschromatographycoupledtomass
spectrometry using a method previously described by Pizarro
et al. (2002). Ketanserinwas determined by liquid chromatogra-
phy coupled tomass spectrometry. Samples (200μL of plasma)
werepurifiedwithOstroPass-throughSamplePreparationPlates
(Waters,MA,USA)and600μLof acetonitrilewith0.1%formic
acid was used as the elution solvent. After mixing, vacuumwas
applied and the collected mixture was evaporated to dryness at
15 psi and 40 °C. Extract was reconstituted with 100 μL of am-
monium formate 0.02% at pH 5 and acetonitrile (50:50 v/v).
Quantification was performed in a HPLC system coupled to a
triple-quadrupole (6410 Triple Quad LC-MS; Agilent) mass
spectrometerwithanelectrospray interface.Thechromatograph-
ic separationwas doneusing aC18 column (Kinetex, 100mm×
3mm× 1.7μm,Phenomenex,CA,USA).Themobilephasewas
ammoniumformate0.02%atpH5andacetonitrile inan isocratic
mode (50:50 v/v) at a flow rate of 0.45 mL/min. All compounds
weremonitored inpositive ionizationusing themultiple reaction
modemass/charge (M + 1/z). Parameters for the identification of
analytes were as follows: ketanserin 396→ 146, 189, 208;
fragmentor (F) 200 V, collision energy (CE) 15 V; and
pirenperone 394→ 119, 159, 187, F200, CE15.
Endocannabinoid concentrations
The analysis of the endocannabinoids AEA and 2-AG in plas-
ma was performed by a validated method previously de-
scribed (Pastor et al. 2014). Briefly, aliquots of 0.5 mL of
plasma were transferred to 12-mL glass tubes, spiked with
deuterated internal standards, diluted with 0.1 M ammonium
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acetate buffer (pH 4.0), and extracted with tert-butyl methyl
ether. The dry organic extracts were reconstituted in 100 μL of
a mixture water:acetonitrile (10:90, v/v) with 0.1% formic acid
(v/v) and transferred to HPLC vials. Twenty microliters was
injected into the LC/MS-MS system. An Agilent 6410 triple
quadrupole (Agilent Technologies, Wilmington, DE, USA)
equipped with a 1200 series binary pump, a column oven,
a nd a coo l e d a u t o - s amp l e r ( 4 °C ) wa s u s ed .
Chromatographic separation was carried out with a
ACQUITY UPLC C18-CSH column (3.1 × 100 mm,
1.8 μm particle size) (Waters, Yvelines Cedex, France) main-
tained at 40 °C with a mobile phase flow rate of 0.4 mL/min.
The composition of the mobile phase was as follows: A: 0.1%
(v/v) formic acid in water; B: 0.1% (v/v) formic acid in aceto-
nitrile. Detection was done by selection reaction monitoring
(SRM). Quantification was performed by isotope dilution.
Deuterated internal standards were obtained from Cayman
Chemical (Ann Arbor, MI, USA), and solvents were from
Merck (Darmstadt, Germany).
Statistical analysis
Data of the word learning task (WLT) and the concentrations
of eCBs entered a general linear model (GLM) repeated mea-
sures ANOVA (SPSS, version 24.0) with pre-treatment (two
levels: ketanserin, placebo) and treatment (two levels:
MDMA, placebo) as main within-subject factors. IR trial
(three levels) was included as extra within-subject factor for
the WLT. Data of the Groninger Sleep Scale (sleep quantity
and sleep quality) entered repeated measures ANOVA with
test day (four levels) as within-subject factor to test whether
participants had an equal amount of sleep quantity and quality
before each test day.
Paired sample t tests were conducted to investigate the
difference in MDMA and ketanserin concentrations in condi-
tions where MDMA or ketanserin was administered alone and
in combination.
The alpha criterion level of statistical significance for all
analyses was set at p = 0.05. Partial eta squared (partial ƞ2) is
reported in case of significant effects to demonstrate the ef-
fect’s magnitude, where 0.01 is defined as small, 0.06 as mod-
erate, and 0.14 as large. Partial eta squared is based on
Cohen’s f which defines small, medium, and large as, respec-
tively, 0.10, 0.25, and 0.50 which corresponds to η2 of 0.0099,
0.0588, and 0.1379 (Richardson 2011).
Results
Word learning task
GLM RM ANOVA analysis revealed a main effect of treat-
ment on immediate recall total (F1, 19 = 5.48, p = 0.03, partial
ƞ2 = 0.22). There was also a main effect of trial on immediate
recall (IR) per trial indicating that performance increased over
trials (F1, 19 = 91.02, p < 0.001, partial ƞ2 = 0.83). Under influ-
ence of MDMA, participants recalled on average 1.6 words
less per trial, and in total 4.8 words less, compared to placebo.
Analysis also revealed a main effect of treatment (F1, 19 =
8.76, p = 0.008, partial ƞ2 = 0.32) on delayed recall (DR).
Participants recalled on average 3 words less, 30 min after
the initial learning phase, compared to placebo. There was
no main effect of pre-treatment or valence, or an interaction
effect between factors. There was no main effect of pre-
treatment or an interaction effect of pre-treatment by treatment
on IR trial, IR total, or DR (Fig. 1a).
Analysis revealed no statistically significant main effect of
treatment, pre-treatment, or their interaction on number of
correct recognized words (Fig. 1b). A main effect of pre-
treatment (F1, 19 = 5.94, p = 0.02, partial ƞ2 = 0.24) was found
on reaction time related to correct recognized words.
Participants were on average 49 ms slower under influence
of ketanserin compared to placebo (Fig. 1c). There was no
main effect of treatment or pre-treatment by treatment interac-
tion on reaction time in the recognition task.
Groninger Sleep Scale
Analysis of the Groninger Sleep Scale, which served as a
control measure, showed no difference in sleep quality (F3,
57 = 2.11, p = 0.11, partial ƞ2 = 0.10) and quantity (F3, 57 =
0.35, p = 0.79, partial ƞ2 = 0.02) between the four test days.
Participants slept on average 6 h and 59 min (SD = 0.9) on the
night prior to a test day, and they had and average sleep quality
score of 2.5 (SD = 2.3).
Pharmacokinetics and endocannabinoid concentrations
Endocannabinoid concentrations
Analyses revealed a main effect of pre-treatment (F1, 11 = 10.6;
p = 0.005; partial ƞ2 = 0.41) on plasmaAEAconcentrations (ng/
mL) assessed after the tests. AEA concentrations were higher
180 min after ketanserin administration compared to placebo.
There were no differences in endocannabinoid (2-AG, AEA)
plasma concentrations at baseline and there were no other main
or interaction effects on 2-AG or AEA concentrations (Fig. 2).
Since visual inspection of the data suggested differences be-
tween baseline concentrations of 2-AG and AEA, and the two
subsequentmeasurements,beforeandafter thecognitive tests,an
extra explorativeGLMwas run to testwhether endocannabinoid
concentrations varied naturally over time. The extra GLMdem-
onstrated a main effect of Bmeasurement^ on 2-AG (F2, 30 =
15.90; p < 0.001; partial ƞ2 = 0.51) and AEA concentrations
(F2, 30 = 13.90; p < 0.001; partial ƞ2 = 0.47). Pairwise compari-
sons revealed that 2-AG baseline concentrations were
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significantly lower compared to measure 2 (before cognitive
tests) andmeasure 3 (after cognitive tests); 2-AG concentrations
did not statistically differ between measurements 2 and 3.
BaselineAEAconcentrationsweresignificantly lowercompared
to the second measurement while there were no differences be-
tween baseline concentrations and the third measure or between
the second and the thirdmeasure.
MDMA and ketanserin blood concentrations
Paired sample t tests showed that MDMA plasma concentra-
tions (ng/mL) did not statistically differ between the MDMA
alone condition (mean (± SE): 90 min post-MDMA: 134.8
(16.6); 150 min post-MDMA: 186.0 (17.7)) and the condition
where MDMAwas combined with ketanserin (mean (± SE):
90 min post-MDMA: 126.7 (15.1); 150 min post-MDMA:
182.9 (14.7)). The same was shown for ketanserin plasma
concentrations (ng/mL) that did not differ between the
ketanserin alone condition (mean (± SE): 90 min post-
MDMA: 54.9 (7.6); 150 min post-MDMA: 64.5 (6.0)) and
the condition where ketanserin was combined with MDMA
(mean (± SE): 90 min post-MDMA: 59.0 (8.8); 150 min post-
MDMA: 61.5 (5.4)).
Discussion
The aim of the present study was to investigate the neurobio-
logical mechanism underlying memory impairment during
MDMA intoxication. Based on previous research, it was hy-
pothesized that MDMAwould cause an increase in eCB con-
centrations together with a decrease in memory performance.
In addition, it was hypothesized that the combination of
MDMA and a 5-HT2A receptor blocker, ketanserin, would
counteract this endocannabinoid release and the memory def-
icit. Findings showed that MDMA caused memory impair-
ment in the verbal word learning task. This effect was a rep-
lication of previous studies using the same dose of MDMA
(75 mg) and the same learning paradigm (Kuypers et al. 2016;
Kuypers and Ramaekers 2005). Contrary to our hypothesis,
MDMA did not affect eCB concentrations nor did ketanserin
block the MDMA-induced memory impairment. Ketanserin
caused an increase in AEA concentrations, 180 min after
administration.
While preclinical studies have shown an elevation in eCB
concentrations (Braida et al. 2005; Braida and Sala 2002), the
present study did not demonstrate a significant increase in
plasma eCB concentrations in healthy recreational drug users
after a single dose of MDMA. This absence of MDMA effects
on eCB concentrations could potentially be attributed to the
difference in dosing and dosing schemes with Bextreme^ dose
and dosing schemes in preclinical research exceeding
Bnormal^ dose ranges in humans (Easton and Marsden
2006; Green et al. 2012). In the study of Nawata and col-
leagues for example, endocannabinoid concentrations were
elevated in mice after treatment with MDMA for seven sub-
sequent days. The resulting memory impairment was reversed
by a CB1 antagonist (Nawata et al. 2010). The MDMA-
induced memory impairment which has consistently been
demonstrated in human placebo-controlled studies seems to
be unrelated to the endocannabinoid system.
Fig. 1 Mean (SE) of number correct recalled words (a), number of cor-
rect recognized words (b), and corresponding reaction times (c) in the
word learning task per treatment condition. PLA placebo, KET ketanserin
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The fact that endocannabinoid concentrations in the present
study were assessed at the peripheral level, in blood plasma,
could be another potential explanation for the absence of
MDMA effects on eCB concentrations. It is possible that pe-
ripheral eCB concentrations might not reflect central concen-
trations accurately and preclinical work has previously shown
that AG and AEA concentrations measured at the peripheral
(plasma) and central level (cerebrospinal fluid (CSF)) did not
correlate significantly (Jumpertz et al. 2011). While assessing
biological parameters at the central level by drawing CSF is
invasive, it is very relevant to conduct these measures and to
compare central and peripheral markers in a placebo-
controlled MDMA study prior to conducting behavioral stud-
ies. This information could fine-tune and optimize the timing
and scheduling of tests.
While anMDMAeffect on eCB concentrations was absent,
data of the 2-AG and AEA concentrations, measured at three
different time points, suggested time-related differences in
concentrations. This motivated an extra statistical analysis in-
cluding the three time points (9:00 am, 11:30 am, and
12:30 pm). It was shown that 2-AG concentrations increased
during the test day and relative to baseline, and that AEA
concentrations decreased. Interestingly, preclinical work has
shown that endocannabinoids have a diurnal release pattern
which is opposite to 2-AG and AEA, with higher AEA con-
centrations in a selection of brain areas (nucleus accumbens,
prefrontal cortex, striatum, and hippocampus) in the dark or
Bactive^ phase and high concentrations for 2-AG during the
light or Bresting^ phase (Valenti et al. 2004). Although this
pattern in rats is opposite to our findings, the fact that eCBs
have a diurnal rhythm is interesting. Human research has also
shown that eCBs have a specific rhythm and our data are in
line with this, with continuously increasing 2-AG concentra-
tions across the morning, peaking in the early- to mid-
afternoon, and decreasing AEA concentrations during the
day (Hanlon et al. 2015; Vaughn et al. 2010).
Preclinical studies have in addition also shown that eCB
concentrations do not only fluctuate over time but display
different release patterns in different brain locations, showing
for example higher AEA concentrations during resting phases
in CSF and hypothalamus, while these concentrations are low
in other brain structures like the hippocampus and the prefron-
tal cortex, both known to play a role in memory (Murillo-
Rodriguez et al. 2006). In addition, preclinical research has
demonstrated that AEA plays a central role in memory con-
solidation, while 2-AG does not (Busquets-Garcia et al. 2011).
The relation between AEA concentrations and CB1 receptor
density is out of phase and dependent on time of day. In the
resting phase, a high CB1 receptor density together with low
AEA concentrations is found in the hippocampus while this
pattern is reversed when the animals are awake and active
(Vaughn et al. 2010). Together, these results suggest that it is
relevant to test memory during the morning, when AEA con-
centrations are high in humans, in addition to other times of
the day, when AEA concentrations are lower, and assess the
expression of the CB1 receptor, in a placebo-controlled
MDMA study in order to know whether diurnal variations in
AEA and CB1 receptor influence or change the MDMA-
induced memory deficit.
Research into the role of eCBs in the MDMA-induced
memory deficit in humans is limited by the absence of ap-
proved CB1 antagonists. Rimonabant, a CB1 receptor
antagonist/inverse agonist, which was approved for weight
control, was withdrawn from the market, in addition to a sus-
pension of its development, after some adverse clinical psy-
chiatric side effects (Janero and Makriyannis 2009). Another
approach to this problem is to administer THC, a partial CB1
and CB2 agonist, or a fatty acid amide hydroxylase (FAAH)
Fig. 2 Mean (± SE) plasma concentrations of 2-AG (a) and AEA (b) in the four treatment conditions, and at baseline, before tests (90 min after
treatment, respectively, 120 min after pre-treatment), and after tests (150 min after treatment, respectively, 180 min after pre-treatment)
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inhibitor, an enzyme involved in the catabolism of AEA, and
MDMA in combination, since both combinations suggestible
lead to an increase in endocannabinoid concentrations (Gobbi
et al. 2005; Pertwee 1997). In animal research, a synergistic
disruptive effect of the THC-MDMA combination was shown
on memory (Young et al. 2005). One human study combining
THC withMDMA did not show a change in the drug-induced
memory effect of the single drugs on an N-back task (working
memory). Interestingly, the subjective effects (e.g., drug
strength, feeling high) did increase after the combined admin-
istration (Dumont et al. 2011). Interestingly, animal research
has shown that order is important in these effects. While do-
pamine concentrations decreased when MDMA was given
prior to THC, this change was not present when THC was
given before MDMA (Robledo et al. 2007). In the study of
Dumont et al. (2011), the first dose of THC (4 mg) was given
concurrently with MDMA (100 mg), while the two subse-
quent doses of each 6 mg followed MDMA administration
by 90 and 180 min. Future research could compare the effects
of pre- and post-dosing MDMA-treated participants with
THC to explore the order effects of the different treatments
and reveal whether the effect on eCB concentrations relates to
substance-induced memory impairment.
Although ketanserin exerted effects on the behavioral and
biological level in the present study, inducing a response speed
reduction in theword recognition task and causing an increase in
AEA concentrations, it did not counteract the MDMA-induced
memory impairment (immediate recall) which is in contrast to a
previous study conducted by our group (van Wel et al. 2011).
Findings of a previous study using the same dose (40 mg) of
ketanserin suggest that this dose is sufficient to block the 5-HT2
receptorandpotentialsubjectiveand/orbehavioraleffectscaused
byaserotonergic substance (Vollenweideret al. 1998).However,
vanWeletal. (2011)useda50-mgdoseandshowedablockadeof
theMDMA-induced memory impairment. This 22% difference
indose resulted inketanserinplasmaconcentrations thatwere1.5
times lower than in the previous study. Scrutinizing behavioral
data of both studies, it became apparent that memory perfor-
mance during placebo (Bbaseline^) was comparable though the
MDMA-induced impairment, relative to placebo, was larger in
the study of vanWel et al. (2011). Performance in the latter study
decreased with 29% compared to a 16% decrease in the present
study. This apparent smaller decrease in memory performance
afterMDMAadministration in thepresent study couldpotential-
ly be attributed to the MDMA concentrations that were 20%
lower. Previously, it was shown that MDMA-induced memory
failures correlated positively withMDMAblood concentrations
(Ramaekers et al. 2009). When MDMAwas combined with
ketanserin, the MDMA-induced decrease in memory perfor-
mance was reduced with 15% while this was only 8% in the
present study.This smallerBgain^ inmemoryperformancecould
then perhaps be attributed to the lower availability of ketanserin
and hence a potentially smaller blockade of the 5-HT2 receptors.
While behavioral and biological data showed some effects of
ketanserin, proving that it had effects on the central level, these
low concentrations in blood were possibly not strong enough to
counteract theMDMA-inducedmemory impairment.
To conclude, current findings suggest that peripheral
endocannabinoids are not related to verbal memory impair-
ment during MDMA intoxication.
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